Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | Fund Letter | Neal KaufmanBaron Health Care Fund | Xenon Pharmaceuticals Inc. $XENE• NASDAQ | BiotechnologyBiotechnology | Short XENE (Xenon Pharmaceuticals Inc.) Biopharmaceutical company Xenon Pharmaceuticals Inc. detracted from performance after voluntarily pausing enrollment of new patients in its Phase 3 depression studies following the emergence of neuropsychiatric adverse events, including confusion, somnolence, ataxia, and rare cases of psychosis. The announcement was... | BEAR | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.